Dementia with cerebrovascular disease: The benefits of early treatment

European Journal of Neurology, Supplement

Volumn 12, Issue 3, 2005, Pages 17-21

  Schindler, Rachel J ^a  

^a PFIZER INC   (United States)

Author keywords

Alzheimer's disease; Cerebrovascular disease; Cognition; Dementia; Donepezil; Early treatment; Multi infarct dementia; Vascular dementia

Indexed keywords

DONEPEZIL; PLACEBO;

CEREBROVASCULAR DISEASE; CHOLINERGIC SYSTEM; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEMENTIA; DISEASE COURSE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; GERMANY; HUMAN; META ANALYSIS; MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PATHOPHYSIOLOGY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW;

EID: 27144484930     PISSN: 14710552     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2005.01323.x     Document Type: Conference Paper

References (27)

1. Bartus RT, Dean RL Jr, Beer B, Lippa AS (1982). The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408-414.
2. Black S, Roman GC, Geldmacher DS et al., (2003). Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 34:2323-2330.
3. Bowler JV, Eliasziw M, Steenhuis R et al. (1997). Comparative evolution of Alzheimer disease, vascular dementia, and mixed dementia. Arch Neurol 54:697-703.
4. Burns A, Rossor M, Hecker J et al. (1999). The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord 10:237-244.
5. Farcnik K, Pratt RD, Perdomo CA, Donepezil 307 and 308 VaD Study Groups (2003). Donepezil provides significant benefits on cognition, global function, and activities of daily living in patients with vascular dementia [abstract]. Int Psychogeriatr 15(Suppl. 2):256.
6. Folstein MF, Folstein SE, McHugh PR (1975). Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198.
7. Frölich L, Klinger T, Berger FM (2004). Treatment with donepezil in Alzheimer patients with and without cerebrovascular disease. Presented at the American Association for Geriatric Psychiatry's 17th Annual Meeting, Baltimore, MD, USA, February 21-24.
8. Kalaria RN, Ballard C (1999). Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord 13(Suppl. 3):S115-S123.
9. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984). Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34:939-944.
10. Nyenhuis DL, Gorelick P (2004). Vascular dementia: a contemporary review of epidemiology, diagnosis, prevention, and treatment. J Am Geriatr Soc 46:1437-1448.
11. Perry EK, Gibson PH, Blessed G, Perry RH, Tomlinson BE (1977). Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J Neurol Sci 34:247-265.
12. Pratt RD, Kumar D, Perdomo CA. (2004). Donepezil-treated vascular dementia patients demonstrate sustained cognitive improvements for 1 year. Presented at the American Association for Geriatric Psychiatry's 17th Annual Meeting, Baltimore, MD, USA, February 21-24.
13. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT (1998). A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 50:136-145.
14. Roman GC (2002). Vascular dementia revisited: diagnosis, pathogenesis, treatment, and prevention. Med Clin North Am 86:477-499.
15. Roman GC (2003). Vascular dementia: distinguishing characteristics, treatment, and prevention. J Am Geriatr Soc 51:S296-S304.
16. Roman GC, Tatemichi TK, Erkinjuntti T et al. (1993). Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN Internatipnal Workshop. Neurology 43:250-260.
17. Rosen WG, Mohs RC, Davis KL (1984). A new rating scale for Alzheimer's disease. Am J Psychiatry 141:1356-1364.
18. Sachdev PS, Brodaty H, Looi JC (1999). Vascular dementia: diagnosis, management and possible prevention. Med J Aust 170:81-85.
19. Sakurada T, Alufuzoff I, Winblad B, Nordberg A (1990). Substance P-like immunoreactivity, choline acetyltransferase activity and cholinergic muscarinic receptors in Alzheimer's disease and multi-infarct dementia. Brain Res 521:329-332.
20. Snowdon DA (2003). Healthy aging and dementia: findings from the nun study. Ann Int Med 139:450-454.
21. Swartz RH, Sahlas DJ, Black SE (2003). Strategic involvement of cholinergic pathways and executive dysfunction: does location of white matter signal hyperintensities matter? J Stroke Cerebrovasc Dis 12:29-36.
22. Tohgi H, Abe T, Kimura M, Saheki M, Takahashi S (1996). Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia. J Neural Transm 103:1211-1220.
23. Waller SB, Ball MJ, Reynolds MA, London ED (1986). Muscarinic binding and choline acetyltransferase in postmortem brains of demented patients. Can J Neurol Sci 13(Suppl. 4):528-532.
24. Wallin A, Alafuzoff I, Carlsson A et al. (1989). Neurotransmitter deficits in a non-multi-infarct category of vascular dementia. Acta Neurol Scand 79:397-406.
25. Wilkinson D, Doody R, Helme R et al. (2003). Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 61:479-486.
26. Xu AJ, Chen Z, Yanai K, Huang YW, Wei EQ (2002). Effect of 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl) -1-propanone fumarate, a novel acetylcholinesterase inhibitor, on spatial cognitive impairment induced by chronic cerebral hypoperfusion in rats. Neurosci Lett 331:33-36.
27. Zhou J, Fu Y, Tang XC (2001). Huperzine A and donepezil protect rat pheochromocytoma cells against oxygen-glucose deprivation. Neurosci Lett 306:53-56.